secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2022-11-29T23:59:59+00:00
Accession:  0001737287-22-000089
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene releases Phase 1 data across CAR T programs; initiates Phase 2 ALPHA2 trial
--------------------------------------------------------------------------------

- Single Dose FCA90 in LBCL achieved 67% ORR, 58% CR; 50% in CR at 6 and 12 months. No Grade 3+ CRS or neurotoxicity.
- ALLO-715 in MM expansion (FCA60): 67% ORR, 42% VGPR+ (all MRD-negative), median DOR 9.2 months, longest 24 months.
- ALLO-316 in RCC CD70+ patients (n=9): 100% disease control, 33% partial responses; generally manageable safety.
- Phase 2 ALPHA2 trial enrolling ~100 LBCL patients; planning pivotal Phase 2 for ALLO-715 and evaluating ALLO-316 expansion.
- Research update: Dagger technology aims to delay AlloCAR T rejection; ALLO-605 trial paused for manufacturing review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000089/0001737287-22-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728722000089/allo-20221129.htm
  HTML page:      https://secwatch.observer/filing/0001737287-22-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer